2017 American Transplant Congress
Can Pre-Treatment CDC Titres Predict Graft Outcomes in HLA Incompatible Transplants?
Introduction: Complement Dependent Cytotoxic (CDC) (non-augmented) cross matching and Flow cytometric (FC) cross matching are two commonly used techniques to identify anti- Human Leucocyte Antigen…2017 American Transplant Congress
HLA Class II Molecules Partner with TLR4 to Stimulate Endothelial Cell Activation and Proliferation.
Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA
Background: Transplant recipients developing donor specific HLA antibodies (DSA) are at a higher risk for acute and chronic antibody-mediated rejection (AMR). DSA contribute to the…2017 American Transplant Congress
Anti-HLA I Antibody Enhances Endothelial Cell-Induced Polarization of Human Monocytes to M2a/c-Like Macrophages.
HLA antibody (Ab)-mediated rejection (AMR) is often characterized by graft-infiltrating macrophages, which correlate with tissue fibrosis. Recent studies suggest they may mainly represent M2-polarized macrophages.…2017 American Transplant Congress
Extended Experience with Tocilizumab (Anti-IL6R) for Difficult to Desensitize (Des) Patients Awaiting HLA Incompatible Kidney Transplant.
Kidney Transplant, Cedars-Sinai Medical Center, LA, CA
INTRODUCTION: ~30% of HS patients fail to respond to DES with IVIG+rituximab. IL6/IL-6R signaling is critical for B-cell differentiation to plasmablasts and IgG production. Tocilizumab…2017 American Transplant Congress
Risk Factors and Consequences of De Novo Anti-HLA Donor Specific Antibodies in Kidney Transplant Recipients: The Force Awakens.
Background: Presence of anti-HLA donor specific antibodies (DSAs) has been associated with inferior kidney transplant outcomes. Identification of risk factors for de novo DSAs could…2017 American Transplant Congress
Low Level Early Onset De Novo DSA's May Not Portend Early Graft Dysfunction in Kidney Transplant Recipients.
Nephrology and Hypertension, Stony Brook Medicine, Stony Brook, NY
Background: The occurrence of anti-HLA de novo DSA (dnDSA) has been associated with the histological features of antibody-mediated rejection (ABMR) on kidney biopsy. The significance…2017 American Transplant Congress
Positive Flow Crossmatch After Negative Virtual Crossmatch -A Single Center Experience.
Pathology and Lab Medicine, London Health Sciences Center, London, ON, Canada
Aims: To determine causes of Flow Cytometry crossmatch (FCXM) after a negative virtual crossmatch (VirXM), even with sensitive solid-phase antibody assay and complete HLA typings…2017 American Transplant Congress
Characterization of Human Plasma Cell Proteasome Adaptations to Proteasome Inhibitor Therapy: A Precision Medicine Approach to Overcome Drug Resistance in Desensitization.
1U of Cincinnati, Cincinnati, OH; 2Cincinnati Children's, Cincinnati, OH
Purpose: Bone marrow niche-resident plasma cells (BMNRPCs) exhibit variable sensitivity to proteasome inhibitor (PI) therapy. Here, we characterized alterations in the gene and protein expression…2017 American Transplant Congress
Complement Binding Activity (C3d, C1q) of De Novo Donor-Specific HLA Antibody Is Associated with Increased Risk of Antibody-Mediated Rejection in Non-Sensitized Kidney Transplant Recipients.
Despite advances in therapeutic strategies and medicine, antibody mediated rejection (AMR) is a leading cause of kidney graft loss. The complement binding activity of donor-specific…2017 American Transplant Congress
Microvascular Inflammation at 4 Months Posttransplant Is Associated with Transplant Glomerulopathy at One and Two Years Independent of Rejection and Donor Specific Antibodies.
Aim: Study factors that are associated with transplant glomerulopathy (TG) in flowcytometric crossmatch negative kidney transplant recipients with no desensitization.Methods:Single center retrospective analysis of characteristics…
- « Previous Page
- 1
- …
- 30
- 31
- 32
- 33
- 34
- …
- 47
- Next Page »